Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
Sparrow, Oxford, Sheffield Conduct Clofutriben Phase 2 DC-MACS Study
Details : The collaboration aims to advance the clinical development of SPI-62 (clofutriben), which is being evaluated for treating autonomous cortisol secretion.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sparrow Completes Phase 2 and Gets Orphan Status for Clofutriben in Cushing’s
Details : SPI-62 (clofutriben) is a potent and selective HSD-1 inhibitor. Currently, it is being evaluated for the treatment of endogenous Cushing’s syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
Details : Prednisolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Polymyalgia Rheumatica.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Prednisolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of autonomous cortisol secretion (ACS), a prevalent yet serious condition caused by the overproduction of cortisol from a benign tumor of the adrenal gland.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-62 is Sparrow’s potent and selective investigational HSD-1 inhibitor, which is investigated in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2023
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-62 demonstrated the ability to reduce intracellular cortisol in the liver and to inhibit HSD-1 in both the brain and adipose tissue, which is investigated for the treatment of ACTH-dependent Cushing’s syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-47 combines HSD-1 inhibitor, SPI-62, with an effective glucocorticoid medicine, prednisolone. While prednisolone serves to relieve pain and inflammation, SPI-62 lowers active steroid levels within vital organs, and thereby mitigate the side effects o...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2023
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-62 is an oral, small molecule, potent HSD-1 inhibitor that is in a Phase 2 clinical trial with prednisolone for polymyalgia rheumatica, a prevalent autoimmune disease that mainly affects people over 50.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Clofutriben
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPI-47 combines SPI-62 with an efficacious glucocorticoid medicine to potentially relieve debilitating inflammation with fewer side effects,aims to achieve the same efficacy of glucocorticoids while mitigating their associated toxicities.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Clofutriben,Prednisolone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPI-62
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Details : SPI-62 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cushing Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : SPI-62
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable